Synthesis of 4-[2-aminoethyl(nitrosamino)]-1-pyridin-3-yl-butan-1-one, a new NNK hapten for the induction of N-nitrosamine-specific antibodies

Bioconjugate Chemistry

Volumn 18, Issue 6, 2007, Pages 2045-2053

  Prodhomme, Emmanuel J F ^a   Ensch, Corinne ^a   Bouche, Fabienne B ^a   Kaminski, Thomas ^b   Deroo, Sabrina ^c   Seek, Pierre ^d   Kirsch, Gilbert ^b   Muller, Claude P ^a  

^a LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

^b UNIVERSITÉ DE LORRAINE   (France)

^c Retrovirology Laboratory Luxembourg   (Luxembourg)

^d UNIVERSITY OF LUXEMBOURG   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

DETOXIFICATION; KETONES; METABOLITES;

ANTIBODIES RESPONSE; D VALUES; FUNCTIONALIZED; IN-VIVO; N-NITROSAMINES; N-OXIDES; POLYCLONAL; PYRIDYL; STRUCTURAL FEATURE; TOBACCO SMOKE;

MONOCLONAL ANTIBODIES;

4 [2 AMINOETHYL(NITROSAMINO)] 1 PYRIDIN 3 YLBUTAN 1 ONE; CARCINOGEN; CIGARETTE SMOKE; DIPHTHERIA VACCINE; HAPTEN; MONOCLONAL ANTIBODY; NITROSAMINE; OXIDE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DETOXIFICATION; HAPTEN CARRIER COMPLEX; IC 50; IMMUNOGENICITY; IMMUNOMODULATION; IN VIVO STUDY; METABOLITE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; SMOKING; STATISTICAL DISTRIBUTION; SYNTHESIS;

NICOTIANA TABACUM;

EID: 36849006606     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc070046i     Document Type: Article

References (37)

1. Hecht, S. S. (1998) Biochemistry, biology and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 11, 560-603.
2. Hecht, S. S. (1994) Metabolic activation and detoxification of tobacco-specific nitrosamines - a model for cancer prevention strategies. Drug Metab. Rev. 26, 373-90.
3. Prokopczyk, B., Trushin, N., Leszczynska, J., Waggoner, S. E., and El-Bayoumy, K. (2001) Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways. Carcinogenesis 22, 107-14.
4. Staretz, M. E., Murphy, S. E., Patten, C. J., Nunes, M. G., Koehl, W., Amin, S., Koenig, L. A., Guengerich, F. P., and Hecht, S. S. (1997) Comparative metabolism of the tobacco-related carcinogens benzo[a]pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol, and N′- nitrosonornicotine in human hepatic microsomes. Drug Metab. Dispos. 25, 154-62.
5. Jalas, J. R., Hecht, S. S., and Murphy, S. E. (2005) Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone, a tobacco specific carcinogen. Chem. Res. Toxicol. 18, 95-110.
6. Hecht, S. S. (1999) DNA adduct formation from tobacco-specific N-nitrosamines. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 424, 127-142.
7. Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N., Hecht, S. S., and Hainaut, P. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21, 7435-51.
8. Cloutier, J.-F., and Castonguay, A. (1998) Modulation of DNA repair by various inhibitors of DNA synthesis following 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone (NNK) induced DNA damage. Chem. Biol. Interactions 110, 7-25.
9. Hecht, S. S., Carmella, S. G., Foiles, P. G., Murphy, S. E., and Peterson, L. A. (1993) Tobacco-specific nitrosamine adducts: studies in laboratory animals and humans. Environ. Health Perspect. 99, 57-63.
10. Peterson, L. A., Thomson, N. M., Crankshaw, D. L., Donaldson, E. E., and Kenney, P. J. (2001) Interactions between methylating and pyridyloxobutylating agents in A/J mouse lungs: implications for 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone-induced lung tumorigenesis. Cancer Res. 61, 5757-63.
11. Hashimoto, K., Ohsawa, K. i., and Kimura, M. (2004) Mutations induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in the lacZ and cII genes of Muta(TM) mouse. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 560, 119.
12. Ren, Q., De Roo, G., Kessler, B., and Witholt, B. (2000) Recovery of active medium-chain-length-poly-3-hydroxyalkanoate polymerase from inactive inclusion bodies using ion-exchange resin. Biochem. J. 349, 599-604.
13. Li, L., Xie, Y., El-Sayed, W. M., Szakacs, J. G., Franklin, M. R., and Roberts, J. C. (2005) Chemopreventive activity of selenocysteine prodrugs against tobacco-derived nitrosamine (NNK) induced lung tumors in the A/J mouse. J. Biochem. Mol. Toxicol. 19, 396-405.
14. Lippman, S. M., and Spitz, M. R. (2001) Lung cancer chemoprevention: an integrated approach. J. Clin. Oncol. 19, 74S-82S.
15. Hecht, S. S. (1997) Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis. Proc. Soc. Exp. Biol. Med. 216, 181-91.
16. Cerny, E. H., Levy, R., Mauel, J., Mpandi, M., Mutter, M., Henzelin-Nkubana, C., Patiny, L., Tuchscherer, G., and Cerny, T. (2002) Preclinical development of a vaccine 'against smoking'. Onkologie 25, 406-11.
17. Cerny, T. (2005) Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 166, 167-75.
18. Hall, W. (2002) The prospects for immunotherapy in smoking cessation. Lancet 360, 1089-91.
19. Maurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., Renner, W. A., Muller, P., and Bachmann, M. F. (2005) A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 35, 2031-40.
20. Kantak, K. M. (2003) Vaccines against drugs of abuse: a viable treatment option? Drugs 63, 341-52.
21. Hieda, Y., Keyler, D. E., Ennifar, S., Fattom, A., and Pentel, P. R. (2000) Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int. J. Immunopharmacol. 22, 809-19.
22. Malin, D. H., Lake, J. R., Lin, A., Saldana, M., Balch, L., Irvin, M. L., Chandrasekara, H., Alvarado, C. L., Hieda, Y., Keyler, D. E., Pentel, P. R., Ennifar, S., Basham, L. E., Naso, R., and Fattom, A. (2001) Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. 68, 87-92.
23. Pentel, P., and Malin, D. (2002) A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration 69, 193-7.
24. Pentel, P. R., Malin, D. H., Ennifar, S., Hieda, Y., Keyler, D. E., Lake, J. R., Milstein, J. R., Basham, L. E., Coy, R. T., Moon, J. W., Naso, R., and Fattom, A. (2000) A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. 65, 191-8.
25. Stetter, H., Kuhlmann, H., and Lorenz, G. (1980) Cyanide catalyzed conjugate addition of aryl aldehydes: 4-(3-pyridyl)-4-oxobutyronitrile. Org. Synth. 59, 53.
26. 2 receptor antagonists and synthetase inhibitors. J. Med. Chem. 37, 26-39.
27. Grabarek, Z., and Gergely, J. (1990) Zero-length crosslinking procedure with the use of active esters. Anal. Biochem. 185, 131-5.
28. Chu, C., Schneerson, R., Robbins, J. B., and Rastogi, S. C. (1983) Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect. Immunol. 40, 245-56.
29. Schneerson, R., Barrera, O., Sutton, A., and Robbins, J. B. (1980) Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152, 361-76.
30. Eby, R. (1995) Pneumococcal conjugate vaccines. Pharm. Biotechnol. 6, 695-718.
31. Kayhty, H., and Eskola, J. (1996) New vaccines for the prevention of pneumococcal infections. Emerg. Infect. Dis. 2, 289-98.
32. Lieberman, J. M., Chiu, S. S., Wong, V. K., Partidge, S., Chang, S. J., Chiu, C. Y., Gheesling, L. L., Carlone, G. M., and Ward, J. I. (1996) Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide- protein conjugate vaccine in young children. A randomized controlled trial. J. Am. Med. Soc. 275, 1499-503.
33. Plotkin, S. A., and Orenstein, W. A. (1999) Vaccines, 3rd ed. Saunders Company, Philadelphia, http://www.us.elsevierhealth. com/index.jsp.
34. Talbot, B., Desnoyers, S., and Castonguay, A. (1990) Immunoassays for proteins alkylated by nicotine-derived N-nitrosamines. Arch. Toxicol. 64, 360-364.
35. De Buck, S. S., Augustijns, P., and Muller, C. P. (2005) Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers. J. Pharmacol. Exp. Ther. 313, 640-6.
36. De Buck, S. S., Bouche, F. B., Brandenburger, A., and Muller, C. P. (2005) Modulation of the metabolism and adverse effects of benzo[a]pyrene by a specific antibody: a novel host factor in environmental carcinogenesis? Carcinogenesis 26, 835-44.
37. De Buck, S. S., and Muller, C. P. (2005) Immunopropylactic approaches against chemical carcinogenesis. Vaccine 23, 2403-6.